The DSG2 Knockout Huh-7 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the Huh-7 human hepatocellular carcinoma cell line with targeted disruption of the DSG2 gene. This model enables loss-of-function studies of desmoglein-2 in a well-characterized epithelial liver cancer background. The polyclonal nature avoids clonal selection bias, providing a representative disruption of DSG2 and is useful for studying heterogeneous knockout effects.
The Huh-7 cell line, established from a 57-year-old Japanese male with well-differentiated hepatocellular carcinoma, exhibits epithelial morphology and is a standard model for investigating liver cancer biology and hepatic metabolism. These cells express key desmosomal proteins, making them particularly suitable for dissecting the role of DSG2 in epithelial adhesion and tissue integrity.
DSG2 encodes desmoglein-2, a calcium-dependent transmembrane cadherin essential for desmosome-mediated cell-cell adhesion. It forms supramolecular complexes with the armadillo proteins plakoglobin (JUP) and plakophilin-2 (PKP2), which recruit desmoplakin (DSP) to link to keratin intermediate filaments, thereby providing mechanical integrity. Upstream regulators such as TP63 and ??-catenin transcriptionally control DSG2 expression, while TGF-?? and calcium signaling modulate desmosome assembly. Downstream, DSG2 influences RhoA GTPase activity and the PI3K/AKT signaling axis. Critically, loss of DSG2 disrupts desmosomal sequestration of ??-catenin, releasing it to translocate into the nucleus and activate TCF/LEF-mediated transcription, thereby driving epithelial-mesenchymal transition and promoting tumor invasion.
In the hepatocellular carcinoma context, this DSG2 knockout polyclonal pool enables detailed investigation of how desmosomal defects contribute to HCC progression, metastasis, and therapeutic resistance. Disruption of DSG2-mediated adhesion is expected to compromise epithelial barrier function, increase migratory and invasive properties, and dysregulate ??-catenin signaling??a pathway frequently activated in liver cancers. Additionally, the model provides insights into desmosome-related pathologies beyond oncology, including arrhythmogenic right ventricular cardiomyopathy and the autoimmune blistering disease pemphigus, where anti-desmoglein antibodies are pathogenic.
Researchers can employ this knockout pool in a variety of experimental modalities: Western blotting to verify reduction or absence of desmoglein-2 protein, immunofluorescence to visualize desmosome component localization, quantitative cell adhesion and dissociation assays, migration and invasion assays such as Transwell or wound-healing, transepithelial electrical resistance measurements to quantify barrier integrity, and dual-luciferase ??-catenin/TCF reporter assays to monitor Wnt pathway activity. Transcriptomic profiling via RNA-seq can comprehensively identify gene expression alterations consequent to DSG2 disruption. These cells are particularly valuable for anti-metastatic compound screening and for mechanistic dissection of EMT regulation. For further technical assistance or product inquiries, please contact Ascent Research.
